Tolvaptan in patients with autosomal dominant polycystic kidney disease

Vicente E Torres; Arlene B Chapman; Olivier Devuyst; Ron T Gansevoort; Jared J Grantham; Eiji Higashihara; Ronald D Perrone; Holly B Krasa; John Ouyang; Frank S Czerwiec; TEMPO 3:4 Trial Investigators; Alexander Maxwell

doi:10.1056/NEJMoa1205511

Tolvaptan in patients with autosomal dominant polycystic kidney disease

Vicente E Torres, Arlene B Chapman, Olivier Devuyst, Ron T Gansevoort, Jared J Grantham, Eiji Higashihara, Ronald D Perrone, Holly B Krasa, John Ouyang, Frank S Czerwiec, TEMPO 3:4 Trial Investigators, Alexander Maxwell

Research output: Contribution to journal › Article › peer-review

861 Citations (Scopus)

Abstract

The course of autosomal dominant polycystic kidney disease (ADPKD) is often associated with pain, hypertension, and kidney failure. Preclinical studies indicated that vasopressin V(2)-receptor antagonists inhibit cyst growth and slow the decline of kidney function.

Original language	English
Pages (from-to)	2407-18
Number of pages	12
Journal	New England Journal of Medicine
Volume	367
Issue number	25
DOIs	https://doi.org/10.1056/NEJMoa1205511
Publication status	Published - 20 Dec 2012

Keywords

Adolescent
Adult
Benzazepines
Double-Blind Method
Female
Glomerular Filtration Rate
Humans
Kidney
Male
Middle Aged
Organ Size
Polycystic Kidney, Autosomal Dominant
Receptors, Vasopressin
Sodium
Young Adult

Access to Document

10.1056/NEJMoa1205511

Cite this

Torres, V. E., Chapman, A. B., Devuyst, O., Gansevoort, R. T., Grantham, J. J., Higashihara, E., Perrone, R. D., Krasa, H. B., Ouyang, J., Czerwiec, F. S., TEMPO 3:4 Trial Investigators, & Maxwell, A. (2012). Tolvaptan in patients with autosomal dominant polycystic kidney disease. New England Journal of Medicine, 367(25), 2407-18. https://doi.org/10.1056/NEJMoa1205511

@article{a2635b9eb6e845c1886861840689ee47,

title = "Tolvaptan in patients with autosomal dominant polycystic kidney disease",

abstract = "The course of autosomal dominant polycystic kidney disease (ADPKD) is often associated with pain, hypertension, and kidney failure. Preclinical studies indicated that vasopressin V(2)-receptor antagonists inhibit cyst growth and slow the decline of kidney function.",

keywords = "Adolescent, Adult, Benzazepines, Double-Blind Method, Female, Glomerular Filtration Rate, Humans, Kidney, Male, Middle Aged, Organ Size, Polycystic Kidney, Autosomal Dominant, Receptors, Vasopressin, Sodium, Young Adult",

author = "Torres, {Vicente E} and Chapman, {Arlene B} and Olivier Devuyst and Gansevoort, {Ron T} and Grantham, {Jared J} and Eiji Higashihara and Perrone, {Ronald D} and Krasa, {Holly B} and John Ouyang and Czerwiec, {Frank S} and {TEMPO 3:4 Trial Investigators} and Alexander Maxwell",

year = "2012",

month = dec,

day = "20",

doi = "10.1056/NEJMoa1205511",

language = "English",

volume = "367",

pages = "2407--18",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachusetts Medical Society",

number = "25",

}

TY - JOUR

T1 - Tolvaptan in patients with autosomal dominant polycystic kidney disease

AU - Torres, Vicente E

AU - Chapman, Arlene B

AU - Devuyst, Olivier

AU - Gansevoort, Ron T

AU - Grantham, Jared J

AU - Higashihara, Eiji

AU - Perrone, Ronald D

AU - Krasa, Holly B

AU - Ouyang, John

AU - Czerwiec, Frank S

AU - TEMPO 3:4 Trial Investigators

AU - Maxwell, Alexander

PY - 2012/12/20

Y1 - 2012/12/20

N2 - The course of autosomal dominant polycystic kidney disease (ADPKD) is often associated with pain, hypertension, and kidney failure. Preclinical studies indicated that vasopressin V(2)-receptor antagonists inhibit cyst growth and slow the decline of kidney function.

AB - The course of autosomal dominant polycystic kidney disease (ADPKD) is often associated with pain, hypertension, and kidney failure. Preclinical studies indicated that vasopressin V(2)-receptor antagonists inhibit cyst growth and slow the decline of kidney function.

KW - Adolescent

KW - Adult

KW - Benzazepines

KW - Double-Blind Method

KW - Female

KW - Glomerular Filtration Rate

KW - Humans

KW - Kidney

KW - Male

KW - Middle Aged

KW - Organ Size

KW - Polycystic Kidney, Autosomal Dominant

KW - Receptors, Vasopressin

KW - Sodium

KW - Young Adult

U2 - 10.1056/NEJMoa1205511

DO - 10.1056/NEJMoa1205511

M3 - Article

C2 - 23121377

VL - 367

SP - 2407

EP - 2418

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 25

ER -

Tolvaptan in patients with autosomal dominant polycystic kidney disease

Abstract

Keywords

Access to Document

Fingerprint

Cite this